For research use only. Not for therapeutic Use.
Pociredir (FTX-6058) is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). Pociredir can induce HbF protein expression in cell and murine models. Pociredir can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia[1][2].
Pociredir inhibits PRC2 via binding to EED, which induces robust HbF protein expression in both cell and murine models[2].
| Catalog Number | I044412 |
| CAS Number | 2490676-18-9 |
| Synonyms | (15R)-21-fluoro-10-(2-methylpyridin-3-yl)-13,17-dioxa-3,5,7,8-tetrazapentacyclo[13.6.1.04,12.05,9.018,22]docosa-1(21),4(12),6,8,10,18(22),19-heptaene |
| Molecular Formula | C22H18FN5O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C22H18FN5O2/c1-12-14(3-2-6-24-12)15-7-19-22(28-11-26-27-21(15)28)25-8-16-17(23)4-5-18-20(16)13(9-29-18)10-30-19/h2-7,11,13,25H,8-10H2,1H3/t13-/m1/s1 |
| InChIKey | JQBUTSBIFNKJMW-CYBMUJFWSA-N |
| SMILES | CC1=C(C=CC=N1)C2=CC3=C(NCC4=C(C=CC5=C4C(CO5)CO3)F)N6C2=NN=C6 |
| Reference | [1]. Boerner LK. Virtual meeting delivers first time drug structures. April 12, 2021. [2]. Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference. |
